UPDATE: Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic ... Benzinga This DMC recommendation is based on a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progression-free survival in patients receiving idelalisib plus rituximab compared to those receiving ... Gilead ends leukemia study after positive results Gilead Stops Cancer Drug Trial Early On Positive Results Gilead Sciences To Stop Phase III Study Of Idelalisib - Quick Facts |
